Key Points Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical ...

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new small ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

DelveInsight’s, “Diabetes Pipeline Insight 2025” report provides comprehensive insights about 200+ companies and 200+ ...

Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...